Phase I trial of Novagali's investigational DME injection begins

Article

Cortiject, Novagali Pharma's investigational treatment for Diabetic Macular Oedema (DME), has successfully been injected into the first patient in its Phase I clinical trial.

Cortiject, Novagali Pharma's investigational treatment for Diabetic Macular Oedema (DME), has successfully been injected into the first patient in its Phase I clinical trial. Cortiject is an injectable emulsion containing a corticosteroid; the open-label, dose-escalation trial, evaluating safety and efficacy, will enrol 15 patients.

Patients in the study will be segmented into three arms, each being treated with different doses of a single intravitreal Cortiject injection. The prodrug will remain in the patient's system for nine months, and follow-up will be for 12 months.

Novagali Pharma received the FDA Investigational New Drug Application (IND) for this trial in January 2008.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Lynda Charters
July 25th 2025
Article

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A magnifying glass enhances stocks on a chart. Concept image for global commercialisation agreement, pharmaceutical distribution in eastern and western hemispheres, Europe and EMEA. Image credit: ©Asma – stock.adobe.com

Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop

Martin David Harp
July 23rd 2025
Article

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The logo for Eye2Gene, an artificial-intelligence powered ophthalmology diagnostic platform for inherited retinal disease, shows DNA helix imagery and an eye. Image credit: Heidelberg Engineering

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern
July 18th 2025
Article

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Frank Kerkhoff, MD, PhD, and visual acuity charts following implantation with the Johnson and Johnson Tecnis Odyssey lens.

Q&A: Early research findings and clinical experiences with a new multifocal IOL

Frank Kerkhoff, MD, PhD ;Hattie Hayes
July 17th 2025
Article

Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens

© 2025 MJH Life Sciences

All rights reserved.